deltatrials
Completed PHASE3 NCT00005970

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Sponsor: Canadian Cancer Trials Group

Conditions Breast Adenocarcinoma HER2 Positive Breast Carcinoma Stage IA Breast Cancer AJCC v7 Stage IB Breast Cancer AJCC v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7
Interventions Aromatase Inhibition Therapy Cyclophosphamide Doxorubicin Hydrochloride Laboratory Biomarker Analysis Paclitaxel Tamoxifen Citrate Trastuzumab
Updated 19 times since 2017 Last updated: Aug 13, 2020 Started: May 19, 2000 Primary completion: Apr 25, 2005 Completion: Jan 27, 2010

This PHASE3 trial investigates Breast Adenocarcinoma and HER2 Positive Breast Carcinoma and is currently completed. Canadian Cancer Trials Group leads this study, which shows 19 recorded versions since 2000 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2020 · 14 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~May 2023 · 28 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — May 2023 [monthly]

    Completed PHASE3

▶ Show 14 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jul 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  4. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Jun 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

  13. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

May 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Cancer Trials Group
  • Cancer and Leukemia Group B
  • Eastern Cooperative Oncology Group
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amarillo, United States , Ann Arbor, United States , Asheville, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Bennington, United States , Bethesda, United States , Billings, United States , Birmingham, United States and 114 more locations